Aeon Biopharma Jumps 19% on FDA Feedback

AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Other Events. Exhibit 99.1 PRESS RELEASE ​ AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450 FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required s

AEON Biopharma received FDA feedback on its biosimilar ABP-450, clarifying the development path. The FDA agreed to consider previous studies as supportive evidence and recommended a pharmacodynamic study. AEON plans to submit an IND for this study in Q4 2026 and aims to streamline development, potentially avoiding a full clinical efficacy study. The company expects to return to the FDA in 2027 with its evidence package.

Aeon Biopharma reported positive results from a stress test comparing its ABP-450 treatment to Botox, showing similar degradation under thermal and oxidative stress. The company plans a multi-lot comparability study. Shares of Aeon were up 1% to 23 cents, with a market cap of $11.8 million.

AEON Biopharma, Inc. (AEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE AEON Biopharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advanceme

Central Retail said its unit Central Food Retail will acquire all AEON (Thailand) ordinary shares, after signing an agreement filed Aug. 7. Completion is expected Sept. 30. MaxValu stores will be rebranded as Tops and integrated. AEON exits Thai supermarkets after 40+ years, while prioritizing Vietnam, where AEON Mall reported FY2024 revenue of about 17.3bn yen (+14%).

Central Retail Corporation (CRC) said, in a Stock Exchange of Thailand filing, that its unit Central Food Retail (CFR) will buy AEON (Thailand) Co Ltd, which operates 30 MaxValu supermarkets and has 890 million baht registered capital. CRC plans to fund the deal with internal cash flow, rebrand stores as Tops, and add 900,000+ customers, plus land and a ready-to-eat processing center.